{"protocolSection":{"identificationModule":{"nctId":"NCT01392300","orgStudyIdInfo":{"id":"MRZ 60201/SP/3001"},"secondaryIdInfos":[{"id":"2010-023043-15","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke","officialTitle":"Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Upper Limb","acronym":"PURE"},"statusModule":{"statusVerifiedDate":"2016-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-09"},"primaryCompletionDateStruct":{"date":"2013-03","type":"ACTUAL"},"completionDateStruct":{"date":"2014-02","type":"ACTUAL"},"studyFirstSubmitDate":"2011-07-07","studyFirstSubmitQcDate":"2011-07-11","studyFirstPostDateStruct":{"date":"2011-07-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-01-13","resultsFirstSubmitQcDate":"2016-01-13","resultsFirstPostDateStruct":{"date":"2016-02-11","type":"ESTIMATED"},"dispFirstSubmitDate":"2014-03-19","dispFirstSubmitQcDate":"2014-03-19","dispFirstPostDateStruct":{"date":"2014-04-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-11-29","lastUpdatePostDateStruct":{"date":"2017-01-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.","detailedDescription":"The study consists of a randomized, double-blind, placebo-controlled, parallel-group, single-dose main period followed by an open-label, non-controlled, repeated-dose extension period (Open-Label Extension Period - OLEX)."},"conditionsModule":{"conditions":["Post-stroke Spasticity of the Upper Limb"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":317,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DB IncobotulinumtoxinA (Xeomin) (400 U)","type":"EXPERIMENTAL","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment","interventionNames":["Drug: IncobotulinumtoxinA (400 Units)"]},{"label":"DB Placebo Comparator","type":"PLACEBO_COMPARATOR","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment","interventionNames":["Drug: Placebo Comparator"]}],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (400 Units)","description":"Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection","armGroupLabels":["DB IncobotulinumtoxinA (Xeomin) (400 U)"],"otherNames":["Xeomin"]},{"type":"DRUG","name":"Placebo Comparator","description":"Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection","armGroupLabels":["DB Placebo Comparator"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow.\n\nThe Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Investigator's Global Impression of Change","description":"This is the co-primary outcome measure. The Global Impression of Change Scale \\[GICS\\] is used to measure the investigator's impression of change due to treatment. The response option is a common 7-point Likert scale that ranges from -3 = very much worse to +3 = very much improved.","timeFrame":"Week 4"}],"secondaryOutcomes":[{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 4"},{"measure":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 8"},{"measure":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 12"},{"measure":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 4"},{"measure":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 8"},{"measure":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","timeFrame":"Week 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Upper limb spasticity\n* Time since stroke greater than 3 months\n* Need for 400 U Botulinum toxin type A\n\nExclusion Criteria:\n\n* Body weight below 50kg\n* Fixed contractures of the upper limb\n* Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin Type A\n* Infection at the injection site","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Expert","affiliation":"Merz Pharmaceuticals GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Merz Investigational Site #001184","city":"Downey","state":"California","zip":"90242","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Merz Investigational Site #001017","city":"Fountain Valley","state":"California","zip":"92728","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Merz Investigational Site #001188","city":"Miami","state":"Florida","zip":"33172","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Merz Investigational Site #001037","city":"Augusta","state":"Georgia","zip":"30912","country":"United States","geoPoint":{"lat":33.47097,"lon":-81.97484}},{"facility":"Merz Investigational Site #001186","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Merz Investigational Site # 001110","city":"Overland Park","state":"Kansas","zip":"66211","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Merz Investigational Site #001198","city":"Stratford","state":"New Jersey","zip":"08084","country":"United States","geoPoint":{"lat":39.82678,"lon":-75.01545}},{"facility":"Merz Investigational Site #001240","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Merz Investigational Site #001009","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Merz Investigational Site #001241","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Merz Investigational Site #001211","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Merz Investigational Site #001245","city":"Chattanooga","state":"Tennessee","zip":"37403","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Merz Investigational Site #001226","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Merz Investigational Site #420046","city":"Brno","zip":"62500","country":"Czech Republic","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Merz Investigational Site #420029","city":"Brno","zip":"65691","country":"Czech Republic","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Merz Investigational Site #420028","city":"Olomouc","zip":"77520","country":"Czech Republic","geoPoint":{"lat":49.59552,"lon":17.25175}},{"facility":"Merz Investigational Site #420024","city":"Ostrava-Poruba","zip":"70852","country":"Czech Republic","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Merz Investigational Site #420025","city":"Pardubice","zip":"53203","country":"Czech Republic","geoPoint":{"lat":50.04075,"lon":15.77659}},{"facility":"Merz Investigational Site #420030","city":"Praha","zip":"12000","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Merz Investigational Site #420045","city":"Praha","zip":"15006","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Merz Investigational Site #420047","city":"Rychnov nad Kneznou","zip":"51601","country":"Czech Republic","geoPoint":{"lat":50.16284,"lon":16.27488}},{"facility":"Merz Investigational Site #049134","city":"Rostock","zip":"18147","country":"Germany","geoPoint":{"lat":54.0887,"lon":12.14049}},{"facility":"Merz Investigational Site #036004","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site # 036009","city":"Budapest","zip":"1204","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Merz Investigational Site #036005","city":"Nyiregyhaza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"Merz Investigational Site #036008","city":"Szeged","zip":"6725","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"facility":"Merz Investigational Site #091003","city":"Porur","state":"Chennai","zip":"600116","country":"India","geoPoint":{"lat":13.03565,"lon":80.15821}},{"facility":"Merz Investigational Site #091006","city":"Bangalore","state":"Karnataka","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Merz Investigational Site #091002","city":"Trivandrum","state":"Kerala","zip":"695011","country":"India","geoPoint":{"lat":8.4855,"lon":76.94924}},{"facility":"Merz Investigational Site #091007","city":"Chennai","state":"Tamil Nadu","zip":"600116","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Merz Investigational Site #091008","city":"Coimbatore","state":"Tamil Nadu","zip":"641014","country":"India","geoPoint":{"lat":11.00555,"lon":76.96612}},{"facility":"Merz Investigational Site #091001","city":"Lucknow","state":"Uttar Pradesh","zip":"226003","country":"India","geoPoint":{"lat":26.83928,"lon":80.92313}},{"facility":"Merz Investigational Site #091004","city":"New Delhi","zip":"110065","country":"India","geoPoint":{"lat":28.63576,"lon":77.22445}},{"facility":"Merz Investigational Site # 048029","city":"Gdansk","zip":"80-254","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Merz Investigational Site #048044","city":"Kielce","zip":"25-103","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Merz Investigational Site #048031","city":"Krakow","zip":"31-505","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048050","city":"Lodz","zip":"90-130","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Merz Investigational Site #048051","city":"Lublin","zip":"20-022","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Merz Investigational Site #048032","city":"Olsztyn","zip":"10-561","country":"Poland","geoPoint":{"lat":53.77995,"lon":20.49416}},{"facility":"Merz Investigational Site #048053","city":"Poznan","zip":"61-485","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Merz Investigational Site #048023","city":"Warszawa","zip":"02-957","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #048052","city":"Warszawa","zip":"04-141","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #048033","city":"Warszawa","zip":"04-749","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #007010","city":"Krasnoyarsk","zip":"660037","country":"Russian Federation","geoPoint":{"lat":56.01839,"lon":92.86717}},{"facility":"Merz Investigational Site #007011","city":"Moscow","zip":"105005","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Merz Investigational Site #007009","city":"St. Petersburg","zip":"129019","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Merz Investigational Site #007005","city":"Stavropol","zip":"355000","country":"Russian Federation","geoPoint":{"lat":45.0428,"lon":41.9734}}]},"referencesModule":{"references":[{"pmid":"26201835","type":"RESULT","citation":"Elovic EP, Munin MC, Kanovsky P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle Nerve. 2016 Mar;53(3):415-21. doi: 10.1002/mus.24776. Epub 2015 Dec 15. Erratum In: Muscle Nerve. 2016 Jun;54(1):170."},{"pmid":"31647185","type":"DERIVED","citation":"Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. IncobotulinumtoxinA Treatment in Upper-Limb Poststroke Spasticity in the Open-Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life. PM R. 2020 May;12(5):491-499. doi: 10.1002/pmrj.12265. Epub 2020 Jan 22. Erratum In: PM R. 2020 Jul;12(7):736."},{"pmid":"30484117","type":"DERIVED","citation":"Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP. IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study. Adv Ther. 2019 Jan;36(1):187-199. doi: 10.1007/s12325-018-0833-7. Epub 2018 Nov 27."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"FG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"FG002","title":"OLEX IncobotulinumtoxinA (Xeomin) (400 Units, 3 Injections)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): OLEX period, three injection sessions - open-label treatment assignment"}],"periods":[{"title":"Main Period (MP)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"210"},{"groupId":"FG001","numSubjects":"107"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"199"},{"groupId":"FG001","numSubjects":"100"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Predefined discontinuation criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Open Label Extension (OLEX) Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Subjects from double-blind arms were switched to arm OLEX IncobotulinumtoxinA (Xeomin) (...)","numSubjects":"0"},{"groupId":"FG001","comment":"Subjects from double-blind arms were switched to arm OLEX IncobotulinumtoxinA (Xeomin) (...)","numSubjects":"0"},{"groupId":"FG002","comment":"Subjects from double-blind arms were switched to arm OLEX IncobotulinumtoxinA (Xeomin) (...)","numSubjects":"299"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"248"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"51"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"13"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"17"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety evaluation set (The subset of all subjects who were exposed to investigational product in the main period)","groups":[{"id":"BG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"BG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"210"},{"groupId":"BG001","value":"107"},{"groupId":"BG002","value":"317"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.3","spread":"11.9"},{"groupId":"BG001","value":"57.8","spread":"10.9"},{"groupId":"BG002","value":"56.1","spread":"11.6"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"181"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"136"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"34"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"279"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"40"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"175"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"266"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"38"}]}]},{"title":"Czech Republic","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"71"}]}]},{"title":"Hungary","categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"32"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"104"}]}]},{"title":"Russian Federation","categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"32"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"India","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"39"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow.\n\nThe Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.06"},{"groupId":"OG001","value":"-0.5","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.7","ciUpperLimit":"-0.3","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.1"}]},{"type":"PRIMARY","title":"Investigator's Global Impression of Change","description":"This is the co-primary outcome measure. The Global Impression of Change Scale \\[GICS\\] is used to measure the investigator's impression of change due to treatment. The response option is a common 7-point Likert scale that ranges from -3 = very much worse to +3 = very much improved.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by zero change (worst case).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.07"},{"groupId":"OG001","value":"0.9","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.003","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.1","ciUpperLimit":"0.5","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.11"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"33"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"4.28","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.43","ciUpperLimit":"7.52"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"34"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.69","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.56","ciUpperLimit":"4.63"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Primary Target Clinical Pattern","description":"Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"22"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.004","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.48","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.33","ciUpperLimit":"4.61"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"31"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.76","ciUpperLimit":"5.57"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"33"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.021","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.92","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.10","ciUpperLimit":"3.34"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Wrist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"17"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.32","ciUpperLimit":"5.05"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"28"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.06","ciUpperLimit":"6.72"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"28"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.40","ciUpperLimit":"4.46"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Flexed Elbow","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"21"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.102","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.70","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"3.22"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"26"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.67","ciUpperLimit":"5.23"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"27"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.002","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.46","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.37","ciUpperLimit":"4.41"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Clenched Fist","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.069","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.95","ciUpperLimit":"3.69"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"21"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.034","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.05","ciUpperLimit":"4.00"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"23"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.169","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.61","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.82","ciUpperLimit":"3.16"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Thumb-in-palm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.920","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"2.18"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 4 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"3.56","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.83","ciUpperLimit":"6.91"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 8 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.28","ciUpperLimit":"4.56"}]},{"type":"SECONDARY","title":"Response Rates on the Ashworth Scale at Week 12 Calculated for the Muscle Group Pronated Forearm","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Subjects with a reduction of one point were defined as responder for the aim of the efficacy analysis.","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by worst case (=non-responder).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"15"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.018","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"2.26","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.15","ciUpperLimit":"4.41"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.06"},{"groupId":"OG001","value":"-0.5","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"-0.2"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.06"},{"groupId":"OG001","value":"-0.4","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.011","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Wrist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.032","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.6","ciUpperLimit":"-0.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Flexed Elbow.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.029","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.06"},{"groupId":"OG001","value":"-0.3","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"-0.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.05"},{"groupId":"OG001","value":"-0.4","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.019","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Clenched Fist.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.137","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.013","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.131","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Thumb-in-palm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.714","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.5","ciUpperLimit":"-0.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.008","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Ashworth Scale Score for Treated Muscle Group Pronated Forearm.","description":"The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.062","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.076","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Disability Assessment Scale - Principal Therapeutic Target Domain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.4","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.416","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.07"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.175","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Hygiene","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.05"},{"groupId":"OG001","value":"-0.1","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.140","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"-0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.07"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.018","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Dressing","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.04"},{"groupId":"OG001","value":"-0.1","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.105","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.3","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.07"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.016","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.2","spread":"0.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.014","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"0.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.08"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Limb Position","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.05"},{"groupId":"OG001","value":"-0.3","spread":"0.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.220","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.07"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 4 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.06"},{"groupId":"OG001","value":"-0.2","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.429","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 8 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 8","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.06"},{"groupId":"OG001","value":"-0.2","spread":"0.08"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.884","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.09"}]},{"type":"SECONDARY","title":"Changes From Baseline to Week 12 in Disability Assessment Scale - Domain Pain","description":"The Disability Assessment Scale consists of the four domains hygiene, dressing, limb position, and pain which were assessed on a 4-point scale with the values 0 (=no disability), 1 (=mild disability), 2 (=moderate disability), and 3 (=severe disability).","populationDescription":"Full Analysis set (all subjects who were randomized after the Amended Protocol Version 3.0, dated 11-MAY-2012 became effective, who were treated, and for whom at least an AS baseline value for the primary target clinical pattern is given). Missing values were imputed by the last observation carried forward (LOCF) approach.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"},{"id":"OG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"88"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.06"},{"groupId":"OG001","value":"-0.2","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.844","statisticalMethod":"ANCOVA","paramType":"Mean Difference (Final Values)","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.2","ciUpperLimit":"0.2","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.10"}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From the timepoint of first injection until 12 weeks +/- 3 days after last injection","description":"The investigator asked the patient for AEs systematically at each visit.","eventGroups":[{"id":"EG000","title":"Double-blind IncobotulinumtoxinA (Xeomin) (400 Units)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment","seriousNumAffected":7,"seriousNumAtRisk":210,"otherNumAffected":6,"otherNumAtRisk":210},{"id":"EG001","title":"Double-blind Placebo Comparator","description":"Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind, randomized treatment assignment","seriousNumAffected":2,"seriousNumAtRisk":107,"otherNumAffected":4,"otherNumAtRisk":107},{"id":"EG002","title":"OLEX IncoboutulinumtoxinA (Xeomin) (400 Units, 3 Injections)","description":"IncobotulinumtoxinA (Xeomin) (400 Units): OLEX period, three injection sessions - open-label treatment assignment","seriousNumAffected":22,"seriousNumAtRisk":296,"otherNumAffected":32,"otherNumAtRisk":296}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":2,"numAtRisk":296}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Peipheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Pancreatic enlargement","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Biliary colic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":2,"numAtRisk":296}]},{"term":"Renal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":1,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Calculus bladder","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":1,"numAtRisk":107},{"groupId":"EG002","numAffected":0,"numAtRisk":296}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Ovarian adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Cardiac death","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Pseudobulbar palsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":210},{"groupId":"EG001","numAffected":0,"numAtRisk":107},{"groupId":"EG002","numAffected":1,"numAtRisk":296}]}],"otherEvents":[{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":107},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":296}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":296}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":210},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":296}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":210},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":107},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":296}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":210},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":107},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":296}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected."},"pointOfContact":{"title":"Public Disclosure Manager","organization":"Merz Pharmaceuticals GmbH","email":"clinicaltrials@merz.de","phone":"+49 69 1503 1"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["France"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000545476","term":"incobotulinumtoxinA"}],"ancestors":[{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","asFound":"Afatinib","relevance":"HIGH"},{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}